| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 174.56 | 7.9% | 69.5% |
| Total Income | 178.34 | 6.7% | 64.9% |
| Expenditure | 133.74 | 5.7% | 52.5% |
| PBT | 44.60 | 9.7% | 117.7% |
| Net Profit | 33.58 | 11.5% | 104.4% |
| OPM | 15.83% | 14.78pp | 11.00pp |
| NPM | 18.83% | 0.81pp | 3.64pp |
| EPS | 7.29 | 11.5% | 44.6% |
Senores Pharmaceuticals Reports Robust Q3 & 9M FY26 Financial Results with 164% & 165% Y-o-Y Growth in EBITDA Respectively
20 Jan 2026 · 20 Jan, 2:12 pm
Summary
Senores Pharmaceuticals, a global research-driven pharmaceutical company, announced its un-audited Financial Results for the 3rd Quarter and nine-months year ended 31st December 2025. The company reported a significant increase in income, EBITDA, and profit after tax for both Q3FY26 and 9MFY26. The cash flow from operations also showed substantial growth. The company has a strong pipeline of products and is expanding its manufacturing footprint through the acquisition of Apnar Pharma. The Emerging Markets business is now cash flow positive with a significant increase in EBITDA margin.
Key Highlights
- 1
164% Y-o-Y growth in EBITDA for Q3FY26
- 2
186% Y-o-Y growth in profit after tax for Q3FY26
- 3
105% Y-o-Y growth in income for Q3FY26
- 4
165% Y-o-Y growth in EBITDA for 9MFY26
- 5
187% Y-o-Y growth in profit after tax for 9MFY26
- 6
110% Y-o-Y growth in income for 9MFY26
- 7
~Rs. 19 crs cash flow from operations for Q3FY26
- 8
~Rs. 51 crs cash flow from operations for 9MFY26
- 9
46 approved ANDAs covering 137 strengths
- 10
Highest-ever Revenue and EBITDA in Emerging Markets business in Q3FY26
- 11
75% stake acquisition of Apnar Pharmaceuticals completed
- 12
Branded Generics business seeing significant growth in India
Management Comments
Swapnil Shah
Managing Director, Senores Pharmaceuticals Limited
Continuing our strong momentum, we delivered a robust performance in Q3FY26, with Revenue growing by 64% and Profit after Tax growing by 86% Y-o-Y... We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharma... The acquisition enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO-CMO opportunities, positioning Senores for sustained growth... We are now approved and supplying to multiple large hospital chains across India... All in all, we have delivered a strong performance in the quarter and nine-months and remain on track to deliver on our full year guidance... We will continue to drive the business on 4 key pillars — (i) Expansion of the ANDA Portfolio in Regulated Markets; (ii) Steady Scale-up of the CDMO/CMO Segment in Regulated Markets; (iii) Portfolio Expansion and Profitability Improvement in Emerging Markets; and (iv) Scale-up of Branded Generics business in India.
Informational and educational content only. Not investment advice.